Chronic Obstructive Pulmonary Diseases - Journal of the COPD Foundation, published by the esteemed COPD Foundation, serves as a vital platform for advancing research in the field of pulmonary and respiratory medicine. With an ISSN of 2372-952X, this journal emphasizes the exploration and dissemination of knowledge related to chronic obstructive pulmonary disease (COPD) while addressing broader topics in respiratory health. Recognized within the Q2 category of the 2023 *Scopus* rankings and positioned at the 47th percentile in its field, the journal showcases innovative studies, clinical insights, and evidence-based practices crucial for professionals, researchers, and students alike. Although operating as a traditional publication, it seeks to provide immediate access to groundbreaking research on the prevention and management of COPD, facilitating improved patient outcomes. As it continues to expand its influence since its convergence in 2018, this journal is dedicated to bridging gaps in pulmonary medicine, making it an indispensable resource for the global respiratory health community.

RESPIRATION is a prestigious journal dedicated to advancing knowledge in the field of Pulmonary and Respiratory Medicine, with a commitment to publishing high-quality, peer-reviewed research. Established in 1944 and published by KARGER in Switzerland, this journal has maintained an exemplary impact within the scientific community, currently holding a Q1 ranking in the 2023 category for Pulmonary and Respiratory Medicine, placing it among the top 18% of journals in its field. With an ISSN of 0025-7931 and an E-ISSN of 1423-0356, RESPIRATION provides a platform for researchers and professionals to disseminate original studies, reviews, and clinical cases that shape contemporary understanding and treatment of respiratory diseases. The journal's rigorous standards for publication ensure that it remains a vital resource for the latest innovations and findings. As part of its mission, RESPIRATION seeks to bridge the gap between clinical practice and research, fostering multidisciplinary collaboration and enhancing patient outcomes. The journal is readily accessible, ensuring that vital research reaches a broad audience of healthcare professionals and academic scholars globally.

Zeitschrift für Pneumologie is a pivotal journal in the field of Pulmonary and Respiratory Medicine, published by Springer Heidelberg, a renowned name in academic publishing. With its ISSN number 2731-7404, it serves as a vital platform for disseminating innovative research and clinical studies relevant to lung health and diseases. This German-based journal aims to bridge the gap between research and practice, encouraging submissions that advance knowledge in respiratory medicine, including pathophysiology, treatment modalities, and patient care strategies. Although currently categorized in the Q4 quartile within its field, its commitment to quality research and emerging insights positions it as an essential resource for researchers, healthcare professionals, and students dedicated to improving respiratory health. The journal operates within the convergence period from 2022 to 2024, promising a dynamic evolution of its content. With limited open access availability, it encourages readership and contribution from its audience, fostering a collaborative academic environment.

Chronic Respiratory Disease is a leading peer-reviewed journal dedicated to advancing the field of pulmonary and respiratory medicine. Published by SAGE Publications Ltd since its inception in 2004, this open-access journal has been at the forefront of disseminating high-quality research aimed at addressing chronic respiratory conditions. With an impressive impact factor and classified as Q1 in the 2023 category of Pulmonary and Respiratory Medicine, it ranks an admirable #45 out of 155 in Scopus, placing it in the 71st percentile of its field. This journal features a diverse range of studies, reviews, and clinical insights that cater to researchers, healthcare professionals, and students alike, encouraging the exchange of innovative ideas and practices in respiratory disease management. Operating out of London, UK, Chronic Respiratory Disease exemplifies a commitment to openness, having transitioned to open access since 2017, thereby ensuring that pivotal research is readily accessible to a global audience engaged in the improvement of respiratory health.

Jornal Brasileiro de Pneumologia is a pivotal open-access journal in the field of Pulmonary and Respiratory Medicine, published by SOC BRASILEIRA PNEUMOLOGIA TISIOLOGIA. Established in 2004, this esteemed publication has become a significant platform for researchers, health professionals, and students in Brazil and beyond, facilitating the exchange of innovative ideas and vital research findings. The journal is indexed in Scopus and is recognized in the 2023 category quartiles as Q3, ranking 86 out of 155 in its field with a corresponding 44th percentile. This reflects its growing influence and commitment to advancing knowledge concerning respiratory health. With a mission to disseminate high-quality research, the journal aims to foster advancements in clinical practice and improve outcomes in pulmonary diseases, making it an essential resource for those dedicated to enhancing the quality of care in respiratory medicine. For those seeking comprehensive access to critical studies and reviews in this domain, the Jornal Brasileiro de Pneumologia remains an invaluable asset.

American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society, is a leading scholarly journal dedicated to advancing the fields of critical care and pulmonary medicine. With an impressive impact factor and recognized in the Q1 quartile for both Critical Care and Pulmonary Medicine, this journal is essential reading for researchers, clinicians, and students invested in innovative practices and therapies in respiratory health. Through high-quality, peer-reviewed research articles, the journal addresses significant contemporary issues in respiratory and critical care, offering unparalleled insights and fostering interdisciplinary collaboration. Although the journal adheres to a traditional subscription model, it remains a cornerstone for those wishing to stay at the forefront of medical science in this vital area. With its extensive historical context since its establishment in 1991 and continuous publication spanning through 2024, the journal is committed to promoting discourse and disseminating knowledge that ultimately enhances patient care and clinical outcomes.

Therapeutic Advances in Respiratory Disease is a prestigious open-access journal published by SAGE Publications Ltd, based in the United Kingdom. Since its inception in 2007, it has established itself as a leading platform for the dissemination of cutting-edge research in the fields of pulmonary and respiratory medicine and pharmacology. With an impressive impact factor and ranking—showing it is in the Q1 quartile in both Pharmacology (medical) and Pulmonary and Respiratory Medicine as of 2023—the journal's commitment to high-quality research is evident. In 2023, it ranks #32 out of 155 in Pulmonary and Respiratory Medicine and #57 out of 272 in Medical Pharmacology, positioning it in the 79th percentile across these disciplines. Open access since 2018, the journal ensures that its valuable content is readily accessible to a global audience of researchers, healthcare professionals, and students, facilitating the rapid exchange of knowledge that is crucial in the ever-evolving landscape of respiratory health. The journal's objectives include advancing understanding of respiratory diseases through innovative research and promoting the development of therapeutic strategies that improve patient outcomes, making it an essential resource for those dedicated to respiratory medicine.

HEART & LUNG is a premier academic journal published by MOSBY-ELSEVIER, focusing on the critical intersections of cardiology, critical care, and respiratory medicine. Since its inception in 1973, the journal has established a significant reputation within the medical community, as evidenced by its impressive Q2 ranking in key categories such as Cardiology and Cardiovascular Medicine, Critical Care and Intensive Care Medicine, and Pulmonary and Respiratory Medicine for the year 2023. With a dedicated readership comprising researchers, healthcare professionals, and students, HEART & LUNG serves as a vital platform for disseminating cutting-edge research, clinical innovations, and comprehensive reviews that influence practice standards and enhance patient care. While it currently does not offer Open Access options, readers can access a wealth of information pivotal to the advancement of medical knowledge and practice through conventional subscription. Explore the latest findings and contribute to the ever-evolving landscape of cardiovascular and respiratory health through this esteemed journal.

The EUROPEAN RESPIRATORY JOURNAL, published by EUROPEAN RESPIRATORY SOC JOURNALS LTD, is at the forefront of advancing knowledge in the fields of pulmonary and respiratory medicine. With its ISSN 0903-1936 and E-ISSN 1399-3003, this esteemed journal has established itself as a leading platform since its inception in 1988, currently converging towards 2024. Ranked in the Q1 category for both Medicine (miscellaneous) and Pulmonary and Respiratory Medicine in 2023, it stands as the 3rd of 155 journals in its field, reflecting an impressive 98th percentile Scopus ranking. The journal boasts a rigorous selection of peer-reviewed articles that encompass innovative research, clinical studies, and reviews, thereby enhancing the understanding and treatment of respiratory diseases. Although it does not currently offer an Open Access option, the journal remains crucial for researchers, clinicians, and healthcare professionals committed to improving respiratory health across Europe and beyond. Join a community dedicated to groundbreaking research and advancements in respiratory medicine.

COPD - Journal of Chronic Obstructive Pulmonary Disease is a premier peer-reviewed journal published by Taylor & Francis Inc. that focuses on the latest advancements in the understanding, diagnosis, and treatment of chronic obstructive pulmonary disease (COPD). As an Open Access journal since 2022, it enhances availability and dissemination of groundbreaking research, allowing researchers, healthcare professionals, and students to access vital information without barriers. The journal has established itself as a significant resource in pulmonary and respiratory medicine, boasting a commendable Q2 ranking in both medicine and specialty areas as of 2023, with an impressive Scopus rank of 66 out of 155. By bridging the gap between scientific exploration and clinical application, COPD aims to foster innovative approaches to managing this prevalent condition, making it an essential publication for those dedicated to improving patient care and advancing respiratory health.